Platelet Sensitivity to Prostacyclin in Breast Tumor Patients
Author Information
Author(s): C. Benedetto, M. Zonca, A.M. Tavella, E. Petitti, M. Massobrio, S. Nigam, T.F. Slater
Primary Institution: Institute of Obstetrics and Gynaecology -Chair A-, University of Turin
Hypothesis
Does hormonal status affect platelet sensitivity to prostacyclin in patients with breast tumors?
Conclusion
Platelet sensitivity to prostacyclin is influenced by the phase of the menstrual cycle, but there are no significant differences between normal subjects and breast cancer patients when hormonal status is accounted for.
Supporting Evidence
- Normal men and women had similar IC50 values for prostacyclin.
- Significant differences in IC50 values were observed between the first and second phases of the menstrual cycle.
- Patients with benign and malignant tumors showed no significant differences in platelet sensitivity when hormonal status was considered.
Takeaway
This study looked at how sensitive platelets are to a substance called prostacyclin in people with breast tumors and healthy individuals, finding that hormones play a big role.
Methodology
The study measured platelet sensitivity to prostacyclin using blood samples from different groups of subjects, including healthy individuals and patients with benign or malignant breast tumors.
Potential Biases
Potential bias due to hormonal status not being controlled in earlier comparisons.
Limitations
The study did not specifically investigate the variation of IC50 with age among women.
Participant Demographics
The study included 26 healthy women, 14 women with benign tumors, 30 women with malignant tumors, and 16 healthy men.
Statistical Information
P-Value
p<0.001 for some comparisons
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website